ArticlePloS one2026
Risk prediction of combined fibrinogen degradation products, thrombomodulin, and maximum amplitude for assessing association with venous thromboembolism in patients with post-traumatic fractures.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVenous thromboembolism (VTE) is a globally prevalent severe disease associated with high morbidity and mortality. Currently, thrombomodulin (TM), fibrinogen degradation product (FDP), thromboelastography have been the subject of several research pertaining to VTE; However, the combined diagnostic efficacy of these tests for VTE remains unclear. Therefore, we proposed to investigate the diagnostic efficacy of TM, FDP, thrombelastography in predicting VTE.
methodsThe patients with traumatic fracture included in the study were divided into a VTE group (n = 44) and a control group (n = 56) based on imaging diagnosis. Spearman correlation was employed to analyze the relationship between coagulation-related markers and thromboelastography indices. Variables were analyzed using multifactorial logistic stepwise regression. Statistically significant indicators were included in the receiver operating characteristic curve to evaluate their diagnostic efficacy for VTE.
resultsThe VTE group showed significantly higher levels of multiple coagulation-related parameters and thromboelastography indices compared to the control group. Specifically, D-dimer levels were 8.87 (4.77, 15.07) mg/L in the VTE group versus 2.36 (1.07, 5.73) mg/L in the control group (P < 0.001), and FDP levels were 36.45 (11.34, 73.75) μg/mL versus 7.96 (4.57, 12.73) μg/mL (P < 0.001). TM levels were also elevated in the VTE group at 11.74 (9.26, 13.27) TU/mL compared to 8.60 (7.20, 11.60) TU/mL in controls (P = 0.001). Among thromboelastography parameters, maximum amplitude (MA) was 72.06 ± 7.61 mm in the VTE group versus 67.03 ± 7.21 mm in controls (P = 0.001), and clot intensity (G) was 13,259.75 (9,346.48, 18,545.83) d/sc versus 9,659.70 (8,009.33, 13,480.40) d/sc (P = 0.004). Conversely, the blood clot formation rate was lower in the VTE group (1.25 [0.83, 1.40] vs. 1.30 [1.10, 1.58], P = 0.037). Linear correlation analysis revealed significant positive associations between platelet counts and both MA (r = 0.612, P < 0.001) and G (r = 0.588, P < 0.001). Multivariate logistic stepwise regression identified FDP (OR = 1.047, 95% CI: 1.025-1.070, P < 0.001), TM (OR = 1.215, 95% CI: 1.033-1.429, P = 0.019), and MA (OR = 1.104, 95% CI: 1.026-1.188, P = 0.008) as independent risk factors for VTE. ROC curve analysis demonstrated that the combined model of these three markers achieved the highest diagnostic efficacy, with an area under the curve (AUC) of 0.860 (95% CI: 0.789-0.931), sensitivity of 70.5%, and specificity of 85.7%.
conclusionCombined testing of FDP, TM, and MA holds clinical significance for clinicians to early predict the risk of VTE in post-traumatic fracture patients and implement preventive measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.